Italia markets closed

Denali Therapeutics Inc. (DNLI)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
38,11-0,37 (-0,96%)
Alla chiusura: 04:00PM EDT
37,86 -0,25 (-0,66%)
Dopo ore: 06:36PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente38,48
Aperto38,36
Denaro38,01 x 1100
Lettera60,80 x 800
Min-Max giorno37,71 - 38,84
Intervallo di 52 settimane20,24 - 56,80
Volume718.434
Media Volume629.006
Capitalizzazione4,701B
Beta (5 anni mensile)1,65
Rapporto PE (ttm)N/D
EPS (ttm)-2,34
Prossima data utili02 nov 2022 - 07 nov 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A68,75
  • GlobeNewswire

    Denali Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

    SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial results for the second quarter ended June 30, 2022, and provided business highlights. “The Phase 1 study of DNL919 (ATV:TREM2) is now underway, making this our third BBB Transport Vehicle (TV)-enabled program,

  • GlobeNewswire

    Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson’s Disease

    BIIB122 is an inhibitor of LRRK2, a potential novel target intended to impact the underlying biology and slow the progression of Parkinson’s diseasePhase 2b LUMA to enroll approximately 640 participants with early-stage Parkinson’s disease; most advanced clinical study of a LRRK2 inhibitor SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), and Biogen Inc. (NASDAQ:BIIB) today announced that dosing has commenced in the global

  • GlobeNewswire

    Denali Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

    SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial results for the first quarter ended March 31, 2022, and provided business highlights. “Recent achievements highlight the broad potential of our BBB-crossing Transport Vehicle (TV) platform and the transition of